2023 World Conference on Lung Cancer (Posters)-EP11.03. Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study

EP11.03. Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study - PDF(Slides)

Back to course

Pdf Summary

The TRACKER study aimed to evaluate the real-world effectiveness of atezolizumab, a treatment for advanced non-small-cell lung cancer (NSCLC), in patients who had previously been treated. The study included 455 patients from 27 hospitals in Spain who were treated with atezolizumab between March 2018 and September 2019. The primary endpoint of the study was overall survival (OS), and secondary endpoints included overall response rate (ORR), duration of response (DoR), treatment-related adverse events (AEs), and progression-free survival (PFS).<br /><br />The study found that the overall response rate was 7.1% and the median duration of response was 7.2 months. The median progression-free survival was 3.38 months, and the OS was 9.08 months. The study also compared the outcomes of different subgroups of patients. Patients who met the eligibility criteria of a previous study (OAK) had longer overall survival than those who did not meet the criteria. Additionally, patients who were treated with atezolizumab beyond radiographic progression had a longer overall survival compared to those who were not.<br /><br />The safety profile of atezolizumab was also assessed in the study. Treatment-related adverse events of any grade occurred in 40.3% of patients, with grade 3/4 adverse events occurring in 4.0% of patients. Treatment-related serious adverse events occurred in 4.1% of patients. No grade 5 immune-mediated adverse events were reported.<br /><br />In conclusion, the TRACKER study provides real-world evidence of the effectiveness of atezolizumab in the treatment of advanced NSCLC in patients who have previously been treated. The study findings suggest that atezolizumab can improve overall survival in these patients, especially in certain subgroups. The safety profile of atezolizumab was manageable, with most adverse events being of low grade.

Asset Subtitle

Enric Carcereny

Meta Tag

Speaker Enric Carcereny

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

TRACKER study

atezolizumab

non-small-cell lung cancer

NSCLC

real-world effectiveness

overall survival

overall response rate

duration of response

treatment-related adverse events

progression-free survival